Clinical Trial Update: A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update investigating A-dmDT390-bisFv(UCHT1) fusion protein with ionizing radiation and pembrolizumab for stage IV melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• A-dmDT390-bisFv(UCHT1) fusion protein
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Angimmune LLC | Conditions: Stage IV Melanoma | Phase 1, Phase 2 | Status: UNKNOWN